Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. (2nd January 2016)

• Record Type: Journal Article
• Authors: Dellis, Athanasios; Papatsoris, Athanasios
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 16:Number 1(2016)
• Page Start: 5
• Page End: 10
• Publication Date: 2016-01-02
• Subjects: Denosumab -- castration-resistant -- prostate cancer -- skeletal-related events -- economics -- cost–effectiveness; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1586/14737167.2016.1123624
• Languages: English
• ISSNs: 1473-7167

Abstract

Abstract : Fortunately, novel agents are nowadays available for the management of patients with castration-resistant prostate cancer (CRPC). Denosumab is a new bone-protective agent, approved for the prevention and management of skeletal-related events. Studies have demonstrated that denosumab has better efficacy and similar rate of adverse effects in comparison with zoledronic acid, which was the standard bone-protective agent. In the present review we study the cost–effectiveness of denosumab in patients with CRPC.